Translating TRAIL-receptor targeting agents to the clinic

Martha W. den Hollander; Jourik A. Gietema; Steven de Jong; Annemiek M. E. Walenkamp; Anna K. L. Reyners; Corina N. A. M. Oldenhuis; Elisabeth G. E. de Vries

doi:10.1016/j.canlet.2012.04.007

Translating TRAIL-receptor targeting agents to the clinic

Martha W. den Hollander, Jourik A. Gietema, Steven de Jong, Annemiek M. E. Walenkamp, Anna K. L. Reyners, Corina N. A. M. Oldenhuis, Elisabeth G. E. de Vries^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

71 Citations (Scopus)

Abstract

The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

Original language	English
Pages (from-to)	194-201
Number of pages	8
Journal	Cancer letters
Volume	332
Issue number	2
DOIs	https://doi.org/10.1016/j.canlet.2012.04.007
Publication status	Published - 28-May-2013

Keywords

TRAIL
Clinical studies
Biomarkers
APOPTOSIS-INDUCING LIGAND
AGONISTIC MONOCLONAL-ANTIBODY
CELL LUNG-CANCER
RECOMBINANT HUMAN APO2L/TRAIL
METASTATIC COLORECTAL-CANCER
ADVANCED SOLID MALIGNANCIES
PHASE-I
FUSION PROTEIN
TUMOR-GROWTH
DEATH

Access to Document

10.1016/j.canlet.2012.04.007

Handle.net

Persistent link

Cite this

@article{d78a0b1349284711b40a6fc94fb63f4d,

title = "Translating TRAIL-receptor targeting agents to the clinic",

abstract = "The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.",

keywords = "TRAIL, Clinical studies, Biomarkers, APOPTOSIS-INDUCING LIGAND, AGONISTIC MONOCLONAL-ANTIBODY, CELL LUNG-CANCER, RECOMBINANT HUMAN APO2L/TRAIL, METASTATIC COLORECTAL-CANCER, ADVANCED SOLID MALIGNANCIES, PHASE-I, FUSION PROTEIN, TUMOR-GROWTH, DEATH",

author = "{den Hollander}, {Martha W.} and Gietema, {Jourik A.} and {de Jong}, Steven and Walenkamp, {Annemiek M. E.} and Reyners, {Anna K. L.} and Oldenhuis, {Corina N. A. M.} and {de Vries}, {Elisabeth G. E.}",

year = "2013",

month = may,

day = "28",

doi = "10.1016/j.canlet.2012.04.007",

language = "English",

volume = "332",

pages = "194--201",

journal = "Cancer letters",

issn = "0304-3835",

publisher = "ELSEVIER IRELAND LTD",

number = "2",

}

TY - JOUR

T1 - Translating TRAIL-receptor targeting agents to the clinic

AU - den Hollander, Martha W.

AU - Gietema, Jourik A.

AU - de Jong, Steven

AU - Walenkamp, Annemiek M. E.

AU - Reyners, Anna K. L.

AU - Oldenhuis, Corina N. A. M.

AU - de Vries, Elisabeth G. E.

PY - 2013/5/28

Y1 - 2013/5/28

N2 - The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

AB - The extrinsic apoptotic pathway can be activated by the endogenous ligand TRAIL (Tumor Necrosis Factor (TNE)-Related Apoptosis-Inducing Ligand) by binding to the death receptors TRAIL-R1 and TRAIL-R2 on the cell surface. This pathway is currently evaluated as an anticancer treatment strategy. Both recombinant human TRAIL and several agonistic antibodies against TRAIL-R1 and R2 have been studied in single agent and combination studies and proved to be safe and well tolerated. In this article, the clinical studies published to date will be reviewed. Also, future perspectives and biomarker studies for selecting patients that will benefit from these agents will be discussed. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

KW - TRAIL

KW - Clinical studies

KW - Biomarkers

KW - APOPTOSIS-INDUCING LIGAND

KW - AGONISTIC MONOCLONAL-ANTIBODY

KW - CELL LUNG-CANCER

KW - RECOMBINANT HUMAN APO2L/TRAIL

KW - METASTATIC COLORECTAL-CANCER

KW - ADVANCED SOLID MALIGNANCIES

KW - PHASE-I

KW - FUSION PROTEIN

KW - TUMOR-GROWTH

KW - DEATH

U2 - 10.1016/j.canlet.2012.04.007

DO - 10.1016/j.canlet.2012.04.007

M3 - Review article

SN - 0304-3835

VL - 332

SP - 194

EP - 201

JO - Cancer letters

JF - Cancer letters

IS - 2

ER -

Translating TRAIL-receptor targeting agents to the clinic

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this